Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2118
- Registration Number
- NCT01018173
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: PlaceboDrug: RO5095932
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01017302
A Study With RO4917523 in Patients With Fragile X Syndrome
Phase 2
Completed
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: Placebo (for RO4917523 ascending doses)Drug: RO4917523Drug: Placebo (for RO4917523 fixed dose)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01015430
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT01014442
- Locations
- 🇩🇪
Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School, Hannover, Germany
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
Completed
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1842
- Registration Number
- NCT01011738
- Locations
- 🇦🇹
Tiroler Landeskrankenanstalten Ges.M.B.H.; Klinische Abt. Für Gaströnterologie & Hepatologie, Innsbruck, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie, Wien, Austria
🇧🇩The Liver Centre, Dhaka, Bangladesh
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01010503
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
Phase 3
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01010061
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Phase 1
Withdrawn
- Conditions
- COPD
- Interventions
- Drug: R7103
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01009424
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1162
- Registration Number
- NCT01007435
- Locations
- 🇺🇸
Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
🇦🇺Royal Prince Alfred Hospital; Rheumatology, Camperdown, New South Wales, Australia
🇺🇸Ohio State University; Dept of Immunology, Columbus, Ohio, United States
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT01006980
© Copyright 2025. All Rights Reserved by MedPath